Journal of Pharmacogenomics & Pharmacoproteomics

Breath tests as companion diagnostics (CDs) for personalizing medication

3^rd International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics

September 01-03, 2015 Valencia, Spain

Anil S Modak

Cambridge Isotope Laboratories Inc., USA

Posters-Accepted Abstracts: J Pharmacogenomics Pharmacoproteomics

Abstract:

Over the last decade, stable isotope labeled substrates have been used as probes for rapid, point of care, non invasive and user friendly phenotype breath tests to evaluate activity of drug metabolizing enzymes. These diagnostic breath tests can be potentially used as companion diagnostics (CDs) by physicians to personalize medications with narrow therapeutic windows, to monitor the progress of disease severity or medication efficacy and to study in vivo the pharmacokinetics of xenobiotics. Several genotype tests have been approved by the FDA over the last 15 years; however, they have not been cleared for use in personalizing medications since they fall woefully short in identifying all non responders to drugs especially for the CYP450 enzymes. The results of a number of novel, non invasive, in vivo, point of care, phenotype 13C-breath tests for evaluating DPD, CYP 2D6 and CYP 2C19 enzyme deficiencies to identify responders/non responders to oncology, psychiatric and cardiovascular medications will be discussed. The CDs will enable physicians to select the ideal drug at ideal dose for optimal clinical outcome. The presentation will include trends and future directions of these CDs breathe tests for a variety of drugs to prevent unnecessary toxicity and enhance efficacy.

Biography :

Email: anilm@isotoep.com